Peptide Comparison
Pentadecapeptide (BPC Analog)vsBPC-157
Nature's tissue-healing peptide from gastric juice—a 15-amino acid powerhouse for recovery
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Pentadecapeptide (BPC Analog)
250 mcg–1000 mcg mcg
BPC-157
250–500 mcg
Frequency
Pentadecapeptide (BPC Analog)
Once daily
BPC-157
Once daily
Administration
Pentadecapeptide (BPC Analog)
Intramuscular injection
BPC-157
Subcutaneous injection
Cycle Length
Pentadecapeptide (BPC Analog)
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
Pentadecapeptide (BPC Analog)
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Pentadecapeptide (BPC Analog)
Moderate human trials (Phase 1-2)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Tissue Repair & Recovery
Angiogenesis (Blood Vessel Formation)
Anti-Inflammatory Effects
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Pentadecapeptide (BPC Analog)
Molecular Formula
C62H98N16O22
Molecular Weight
1419.5 g/mol
Half-Life
Not precisely established in humans; likely hours to days depending on tissue depot
Bioavailability
Significantly improved with parenteral administration (injection); poor with oral route
CAS Number
Not assigned (research compound)
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Pentadecapeptide (BPC Analog)
BPC-157
Applications
Best
suited for
Pentadecapeptide (BPC Analog)
Recovering from sports injuries or muscle strains
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on recovering from sports injuries or muscle strains. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting post-surgery tissue repair
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on supporting post-surgery tissue repair. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Accelerating tendon and ligament healing
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on accelerating tendon and ligament healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving overall recovery speed
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on improving overall recovery speed. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Pentadecapeptide (BPC Analog)
Common
- Injection site irritation
- Headache
- Nausea
Uncommon
- Dizziness
- Mood or anxiety changes
Serious
- Allergic reaction
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Pentadecapeptide (BPC Analog)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
BPC-157 analogs show favorable safety in animal toxicity studies with LD50 >1000 mg/kg (oral, rats). No serious adverse events in limited clinical case reports; mild local injection site effects observed. Gastroprotective mechanism suggests low systemic toxicity; rapid hepatic metabolism limits systemic exposure. Preclinical studies show no mutagenicity, carcinogenicity, or teratogenicity; reproductive safety appears favorable.
Contraindications
- xActive cancer or high cancer risk
- xPregnancy or breastfeeding
- xKnown hypersensitivity to peptides
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Pentadecapeptide (BPC Analog) if...
- Recovering from sports injuries or muscle strains
- Supporting post-surgery tissue repair
- Accelerating tendon and ligament healing
- Improving overall recovery speed
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health